Last quarter (Q3 2024), Medexus Pharmaceuticals Inc's total revenue was $25.21M, a decrease of -12.25% from the same quarter last year. In Q3, Medexus Pharmaceuticals Inc's net income was $-534.00K. See Medexus Pharmaceuticals Inc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20
Total Revenue	$ 115.72M	$ 108.10M	$ 76.70M	$ 79.66M	$ 55.51M
Cost of Revenue	$ 54.50M	$ 48.06M	$ 38.77M	$ 37.66M	$ 24.36M
Gross Profit	$ 61.23M	$ 60.04M	$ 37.93M	$ 42.01M	$ 31.14M
Operating Expense	$ 48.53M	$ 52.42M	$ 51.17M	$ 41.27M	$ 32.28M
Operating Income	$ 12.70M	$ 7.61M	$ -13.25M	$ 731.00K	$ -1.14M
Net Non Operating Interest Income Expense	$ -14.75M	$ -13.61M	$ -12.22M	$ 9.82M	$ -6.65M
Other Income Expense	$ -1.02M	$ -2.64M	$ -18.64M	$ -22.42M	$ 2.24M
Pretax Income	$ -872.00K	$ -5.04M	$ -8.73M	$ -31.50M	$ -5.54M
Tax Provision	$ -6.75M	$ -6.26M	$ 1.29M	$ -3.24M	$ -844.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ 5.88M	$ 1.22M	$ -10.03M	$ -28.26M	$ -4.70M
Basic EPS	$ 0.30	$ 0.06	$ -0.15	$ -1.86	$ -0.30
Diluted EPS	$ 0.27	$ 0.06	$ -0.14	$ -1.86	$ -0.30
Basic Average Shares	$ 84.78M	$ 19.98M	$ 19.45M	$ 15.20M	$ 14.36M
Diluted Average Shares	$ 86.98M	$ 20.52M	$ 19.86M	$ 15.20M	$ 14.36M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 52.61M	-	$ 89.95M	$ -78.93M	$ 56.64M
Net Income From Continuing And Discontinued Operation	$ 5.88M	$ 1.22M	$ -10.03M	$ -28.26M	$ -4.70M
Normalized Income	$ -7.95M	$ -11.30M	$ -4.67M	$ -30.97M	$ -6.60M
Interest Expense	-	-	-	-	$ 6.87M
EBIT	$ 13.88M	$ 8.56M	$ 3.49M	$ -21.68M	$ 1.32M
EBITDA	$ 19.72M	$ 14.65M	$ 9.64M	$ -15.71M	$ 5.25M

Currency in USD

Medexus Pharmaceuticals Inc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing